Proteinuria: Clinical signficance and basis for therapy

Singapore Medical Journal

Volumn 42, Issue 8, 2001, Pages 385-389

  Woo, K T ^a   Lau, Y K ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

ACE inhibitor; Angiotensin II receptor antagonist; Disease progression; Proteinuria; Therapy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA;

CELL PROLIFERATION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; GLOMERULONEPHRITIS; GLOMERULOPATHY; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS FILTRATION; HEMATURIA; HEMODYNAMICS; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; PROGNOSIS; PROTEINURIA; REVIEW; RISK FACTOR; URINALYSIS;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY TUBULES, PROXIMAL; PROTEINURIA; RECEPTORS, ANGIOTENSIN; TREATMENT OUTCOME;

EID: 0034751808     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Woo KT, Lau YK, Lee GSL, Wei SS, Lim CH. Pattern of proteinuria in IgA nephritis by SDS-PAGE: Clinical Significance. Clin Nephrol 1991;36:6-11.
2. Woo KT, RPS Edmondson, AYT Wu, GSC Chiang, HS Pwee, CH Lim. The natural history of IgA nephritis in Singapore. Clin Nephrol, 1986; 25:15-21.
3. Cameron JS, Turner DR, Heaton J, Williams DG, Ogg CS, Chantler C, Haycock GB, Hicks J. Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. Am J Med, 1983; 74:175-92.
4. Ruilope LM, Alcazar JM, Hernandez E, Moreno F, Martinez MA, Rodicio JL. Does an adequate control of blood pressure protect the kidney in essential hypertension? J Hypertens 1990; 8:525-31.
5. Mathiesen ER, Ronn B, Storm B, Foght H, Deckert T. The natural course of microalbuminuria in insulin-dependent diabetes: A 10-year prospective study. Diab Med 1995; 12:482-7.
6. Forsblom CM, Groop PH, Ekstrand A, Groop LC. Predictive value of microalbuminuria in patients with insulin-dependent diabetes of long duration. Brit Med J 1992; 305:1051-3.
7. Gall MA, Hougaard P, Borchjohnsen K, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus - prospective, observational study. Brit Med J 1997; 314:783-8.
8. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997; 51:2-15.
9. Jackle I, Gunther H, Von Gise H, Alt JM, Bohle A, Stolte H. Kidney function and protein excretion in relation to pathomorphology of glomerular diseases. Contrib Nephrol 1988; 68:128-35.
10. Bohle A, Von Gise H, Mackensen-Haen S, Stark-Jakob B. The obliteration of the post-glomeruli and tubuli functional interpretation of morphologic findings. Kin Wochenschr 1981; 59:1043-51.
11. Heptinstall RH. Chronic glomerulonephritis, end-stage kidney and visceral changes in chronic renal failure, in Pathology of the Kidney (3rd ed), edited by Heptinstall RH, Boston, Little, Brown and Co. 1983; pp:601-36.
12. Mackensen-Haen S, Bohle A, Christensen J, Wehrmann M, Kendziorra H, Kokot F. The consequences for renal function of widening of the interstitium and changes in the tubular epithelium of the renal cortex and outer medulla in various renal diseases. Clin Nephrol 1992; 37:70-7.
13. Bohle A, Wehrmann M, Bogenschutz O, Batz C, Muller CA, Muller GA. The pathogenesis of chronic renal failure in diabetic nephropathy; Investigation of 488 cases of diabetic glomerulosclerosis. Pathol Res Pract 1991; 187:252-9.
14. Woo KT, Lau YK, Yap HK, Lee GSL, Chiang GSC, Lim CH. Protein selectivity: A prognostic index in IgA nephritis. Nephron 1989; 52:300-6.
15. Nakamura T, Takahashi T, Fukui M, Ebihara I, Osada S, Tomino Y, Koide H. Enalapril attenuates increased gene expression of extracellular matrix components in diabetic rats. J Am Soc Nephrol 1995; 5:1492-7.
16. Ruiz-Ortega M, Gonzalez S, Seron D, Condom E, Bustos C, Largo R, Gonzalez E, Ortiz A, Egido J. ACE inhibition reduces proteinuria. glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis. Kidney Int 1995; 48:1778-91.
17. Deen WM, Bridges CR, Brenner BM, Myers BD. Heteroporous model of glomerular size selectivity: Application to normal and nephrotic humans. Am J Physiol 1985; 249:F374-89.
18. Remuzzi A. Mathematical description of transport of water and macromolecules through the glomerular capillary wall. Curr Opin Nephrol Hypertens 1995; 4:343-8.
19. Bjorck S, Mulec H, Johnsen SA, Norden G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. Br Med J 1992; 304:339-43.
20. Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 1994; 271:275-9.
21. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329:1456-62.
22. Bakris GL, Copley JB, Vicknair N. Blood pressure reduction and progression of diabetic nephropathy in african americans(AA): A five year follow-up (abstract) J Am Soc Nephrol 1995; 6:446.
23. Bakris GL, Copley JB, Vicknair N, Leurgans S. Effect of nondihydropyridine calcium antagonists (NDCAs) on progression of nephropathy from noninsulin dependent diabetes (NIDDM). (abstract) J Am Soc Nephrol 1995; 6:446.
24. Werner K. Public Affairs Home Page Press Release (Merck). Cozaar significantly reduced progression of kidney disease in patients with most common form of diabetes: wysiwyg://8/http://pubaff.merck.com/ media/051901.htm
25. Praga M, Hernandez E, Montoyo C, Andres A, Rulope LM, Rodicio JL. Long term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 1992;20:240-248.
26. Morelli E, Loon N, Meyer T, Peters W, Myers BD. Effects of converting-enzyme inhibition on barrier function in diabetic glomerulopathy. Diabetes 1990; 39:76-82.
27. Remuzzi A, Perticucci E, Ruggenenti P, Mosconi L, Limonta M, Remuzzi G. Angiotensin-converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. Kidney Int 1991; 39:1267-73.
28. Heeg JE, De Jong PE, Van Der Hem GK, De Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989; 36:272-9.
29. Weidmann P, Schneider M, Bohlen L. Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: An updated meta-analysis. Nephrol Dial Transplant 10 (Suppl 9) 1995; 39-45.
30. Woo KT, Lau YK, Wong KS, Chiang GSC. ACE/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis: Kidney Int 2000; 58:2485-91.
31. Vleming LJ, Van Kooten C, Van Dijik M. The D-allele of the ACE gene polymorphism predicts a stronger antiproteinuric response to ACE inhibitors. Nephrology 1998; 4:143-9.
32. Yoshida H, Mitarai T, Kawamura T. Role of the deletion polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy J. Clin. Invest. 1995; 96:2162-9.
33. Moriyama T, Kitamura H, Ochi S. Association of angiotensin I-converting enzyme gene polymorphism with susceptibility to antiproteinuric effect of angiotensin I-converting enzyme inhibitors in patients with proteinuria. J. Am. Soc. Nephrol. 1995; 6:1674-8.
34. Nakamura T, Obata J, Kimura H, Ohno S, Yoshida Y, Kawaihi H. Shimizu F. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis. Kidney Int. 1999; 55:877-89.